摘要 |
Heterocyclic-substituted bi or tricyclics of the formula (I) or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein ------ represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A<SUB>n</SUB>, M<SUB>n</SUB>, U<SUB>n</SUB>, G<SUB>n</SUB>, J<SUB>n</SUB>, K<SUB>n</SUB>, R<SUP>9</SUP>, R<SUP>10</SUP>, R<SUP>11</SUP>, R<SUP>32</SUP>, R<SUP>33</SUP>, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed. |